• Institutional Shareholder Services (ISS) awarded MedinCell “Prime” status for its ESG (Environment, Social and Governance) performance.
• This performance places MedinCell among the 10% of the most virtuous companies in the pharmaceutical and biotechnology industry.
• ISS ESG, one of the world’s leading sustainable investment rating agencies, provides investors with a concrete and relevant assessment of ESG performance.
• MedinCell is a technological pharmaceutical company with 150 employees of 30 different nationalities, all shareholders.
• The first product based on MedinCell’s long-acting injectable technology is expected to obtain FDA marketing authorization by April 2023; two other products are in phase 3, and several others in development.
To receive all of MedinCell’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.